SUNNYVALE, Calif., April 30, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that it has signed an agreement with MIM Software Inc. to further develop adaptive therapy software for the TomoTherapy® and CyberKnife® product portfolios. The new software solution will leverage both Accuray and MIM technology. This is Accuray's second collaboration with MIM; the previous partnership led to the development of the first iPad-based treatment plan review capability, PlanTouch™.
"Accuray is committed to bringing innovative products and services to the market that deliver value to our customers and clinical benefits to their patients," said Joshua H. Levine, president and chief executive officer of Accuray. "We are excited to collaborate with MIM to enhance the ability of our precise, innovative tumor treatments to deliver even better tailored radiation therapy and improved outcomes for some patients."
MIM Software Inc. is a respected vendor of software for the radiation oncology, radiology, and nuclear medicine markets. Since its inception in 2001, the company has made a commitment to advancing the healthcare field. MIM prides itself on its record of major innovations that have advanced the company's primary goal of enhancing patient care, including the development of automated adaptive therapy software. The software allows a sophisticated analysis based upon pre-treatment imaging that enables the clinician to determine whether changes in the patient's anatomy over the course of therapy could reduce the effectiveness of the treatment. In the case of significant changes, the treatment plan would be modified to account for the changes, and this would result in reduced dose to organs at risk and/or optimized dose delivered to the disease, which could, potentially, improve outcomes for patients.
About the CyberKnife® and TomoTherapy® Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
Further information on Accuray, the CyberKnife and TomoTherapy Systems is available at www.accuray.com.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to new order growth, revenue growth, market success, adoption of our new products, clinical benefits of our technologies, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated